Results 71 to 80 of about 20,462 (241)

Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS): “a case report from Ireland with review of literature, clinical pitfalls and future direction”

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021
Background Progressive multifocal leukoencephalopathy (PML) is one of the most serious treatment-related complications that is encountered in patients with multiple sclerosis (MS).
Salman Mansoor, Gerard Mullane, Mohammad Hijaz Adenan, Siobhan Kelly, Aine Water, Grainne McPartland, Kevin Murphy   +6 more
doaj   +1 more source

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. [PDF]

, 2011
Despite its common use in nonmyeloablative preparative regimens, the pharmacokinetics of fludarabine are poorly characterized in hematopoietic cell transplantation (HCT) recipients and exposure-response relationships remain undefined.
Brunstein, CG, Cao, Q, Green, KG, Jacobson, PA, Long-Boyle, JR, McGlave, PB, Miller, JS, Rogosheske, J, Wagner, JE, Weisdorf, DJ   +9 more
core   +1 more source

From Clinical Presentation to the Outcome: the Natural History of PML in a Portuguese Population of HIV Infected Patients [PDF]

, 2011
Background Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system, associated with immunosuppression states.
Almeida, I., França, M., Nery, F., Vasconcelos, c.   +3 more
core   +2 more sources

A Multi‐Center Retrospective Cohort Study of Neurosarcoidosis Myelitis: Current Observations and Future Directions

Annals of Clinical and Translational Neurology, Volume 12, Issue 12, Page 2589-2599, December 2025.
ABSTRACT Objective The optimal treatment for neurosarcoidosis myelitis is uncertain. We characterize incident neurosarcoidosis myelitis and assess treatment response by MRI and clinical scales. Methods Incident probable or definite neurosarcoidosis myelitis in adults was retrospectively identified from 13 academic medical centers.
Giovanna S. Manzano, Denis Balaban, Yihan Zhang, Brian Healy, Bart K. Chwalisz, Michael Levy, Nagagopal Venna, Barney J. Stern, Carlos A. Pardo, Paula Barreras, Nicole Bou Rjeily, Eoin P. Flanagan, Vyanka Redenbaugh, Allen J. Aksamit Jr., Spencer Hutto, Max Herman, Sally El Sammak, Elsa C. Rodriguez, Laura Snider, Hannah Rains, Mayra Montalvo, Torge Rempe, Sergi Martinez Ramirez, Lucas Horta, Stacey Clardy, Jennifer Lord, Tracey A. Cho, Lama Abdel Wahed, Joseph R. Berger, Rohini D. Samudralwar, Noellie Rivera Torres, David B. Clifford, Steven Richard Dunham, Masoud Majed, Aram Zabeti, Samuel Marcucci, Yang Mao‐Draayer, Jon Doty, Paunel B. Agyei, Shamik Bhattacharyya   +39 more
wiley   +1 more source

Progressive multifocal leukoencephalopathy developing in a fludarabine naïve patient with chronic lymphocytic leukemia

International Journal of General Medicine, 2009
Melissa G Ooi1, Peter J Kelly2, Michael Farrell3, Philip Murphy4, Peter O’Gorman11Department of Hematology; 2Department of Neurology, Mater Misericordiae Hospital, Dublin, Ireland; 3Department of Neuropathology; 4Department of Hematology ...
Melissa G Ooi, Peter J Kelly, Michael Farrell, Philip Murphy, Peter O’Gorman   +4 more
doaj  

Progressive multifocal leukoencephalopathy presenting with confusion and behavioral disturbances in an HIV-negative patient [PDF]

, 2023
Ana Isabel Almeida, José Maria Sousa, Sofia Vedor, Luís Augusto   +3 more
openalex   +1 more source

Refractory Status Epilepticus and Therapeutic Uncertainties: a Comprehensive Review on Targeting Neuroinflammation and Rationale for Developing a Platform Trial

Advanced Science, Volume 12, Issue 47, December 18, 2025.
Refractory status epilepticus (RSE) is a life‐threatening neurological emergency with high rates of death and long‐term disability, but treatments for it are often based on limited evidence. RSE is now understood to involve neuroinflammation, which has led to the exploration of anti‐inflammatory and immunomodulatory agents like Tocilizumab. Traditional
Shanika Samarasekera, Suneesh Thilak, Asha Patel, Prashant Nasa, Zubair Ahmed, Lorraine Jacques, William J. Scotton, Cyril Chacko, Randeep Mullhi, Ruoling Chen, Vikram Patil, Suresh Renukappa, Tonny Veenith   +12 more
wiley   +1 more source

Early Magnetic Resonance Detection of Natalizumab-Related Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Sclerosis

Case Reports in Radiology, 2013
Diagnosis of progressive multifocal leukoencephalopathy is usually based on the clinical presentation, on the demonstration of the brain lesions at the magnetic resonance imaging examination, and on the detection of the JC virus DNA in the cerebrospinal ...
Guglielmo Manenti, Simone Altobelli, Marco Nezzo, Marco Antonicoli, Erald Vasili, Luca Neroni, Roberto Floris, Giovanni Simonetti   +7 more
doaj   +1 more source

Progressive Multifocal Leukoencephalopathy in an Immunocompetent Patient

Case Reports in Neurology, 2013
Background: Progressive multifocal leukoencephalopathy (PML) is a rapidly progressive, potentially fatal, demyelinating disease affecting immunosuppressed patients.
Krisztina K. Johansen, Sverre H. Torp, Jana Rydland, Jan O. Aasly   +3 more
doaj   +1 more source

Transforming Pharmacovigilance With Pharmacogenomics: Toward Personalized Risk Management

Clinical Pharmacology &Therapeutics, Volume 118, Issue 6, Page 1286-1296, December 2025.
Pharmacovigilance is a critical component of medication safety. Despite rigorous evaluation of new drugs during clinical trials, some adverse effects might only be identified once pharmaceuticals are used by a larger population for a longer duration.
Claire Spahn, Nanase Toda, Blaine Groat, Omar Aimer, Sara Rogers, Akinyemi Oni‐Orisan, Andrew Monte, Nancy Hakooz, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +8 more
wiley   +1 more source